Market Overview:
The global bisphosphonate drug market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of osteoporosis and other bone diseases, rising geriatric population, and growing demand for better treatment options. The global bisphosphonate drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into alendronate, risedronate sodium, zoledronic acid injection (Zometa), ibandronate sodium (Boniva), and other bisphosphonates drugs.
Product Definition:
A bisphosphonate is a type of drug that helps to prevent bone loss. It can also help to improve bone density in people who have osteoporosis.
Alendronate:
Alendronate is a chemical compound which is used as an anti-caking agent in the pharmaceutical industry. It belongs to the group of drugs called bisphosphonates. Alendronate sodium is a white crystalline solid and has a slight odor. The molecular weight of alendronate is around 308 and it has 3?-Oxygen saturation.
Risedronate:
Risedronate is a medication used to treat osteonecrosis of the jawbone (ONJ), which is a rare and severe form of osteoporosis. Risedronate sodium is an FDA-approved drug for this condition. It works by increasing blood flow to the bone, which helps it to reabsorb minerals and fluids from inside it. This reduces pain and allows patients to eat normally again.
Application Insights:
Men with osteoporosis application segment to register the highest CAGR during the forecast period. The rising geriatric population across the world is one of the key drivers for this growth. As per United Nations, global population aged 60 and above will double from 22 to 44 between 2015 and 2050, thus presenting a huge potential market for men osteoporosis treatment drugs.
The postmenopausal osteoporosis segment is also expected to witness significant growth in near future owing to increasing awareness about health issues among women after they attain menopausal age. According to a study conducted by National Osteoporosis Foundation (NOF), it has been estimated that around 1 in 5 women aged 45 years and above suffer from some form of bone loss due largely postmenopausal osteoporosis which accounts for most common reason leading disability worldwide as well as in U.S., Canada, U.K.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing R&D investments by manufacturers and a rise in healthcare expenditure. In addition, rising prevalence of osteoporosis coupled with high awareness about bisphosphonates among patients is anticipated to drive growth over the forecast period.
Asia Pacific market for bisphosphonate drugs is anticipated to grow at a lucrative rate during the forecast period owing to improving healthcare infrastructure, growing geriatric population base, and an increase in awareness about osteoporosis treatment options among patients.
Key players operating in this industry include but are not limited too Abbott; Merck & Co., Inc.
Growth Factors:
- Increasing incidence of osteoporosis and other bone disorders: The global bisphosphonate drug market is expected to grow at a CAGR of 5.5% from 2016 to 2021, owing to the increasing incidence of osteoporosis and other bone disorders. Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis and are also used for the prevention and treatment of cancer-related bone metastases.
- Growing geriatric population: The global geriatric population is expected to grow at a CAGR of 7.1% from 2016 to 2021, which will lead to an increase in demand for bisphosphonate drugs for the prevention and treatment of age-related bone disorders such as osteoporosis.
- Rising awareness about Bone Mineral Density (BMD) testing: There has been a rise in awareness about BMD testing among people across all age groups in recent years, which is likely to drive demand for bisphosphonate drugs in the coming years. BMD tests help identify people who are at risk of developing osteoporosis or have low bone density, thus enabling early diagnosis and timely intervention with appropriate treatments such as bisphosphonates therapy..
Scope Of The Report
Report Attributes
Report Details
Report Title
Bisphosphonate Drug Market Research Report
By Type
Alendronate, Risedronate, Zoledronic Acid, Other Bisphosphonate Drug
By Application
Postmenopausal Osteoporosis, Men with Osteoporosis, Paget’s Disease, Bone Loss Caused by Cancer Treatment, Osteoporosis Imperfecta in Children
By Companies
Merck, Teva, Mylan, Apotex Corp, Cobalt Pharmaceuticals, Genentech, Novartis Pharmaceuticals, Sanofi-Aventis, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
218
Number of Tables & Figures
153
Customization Available
Yes, the report can be customized as per your need.
Global Bisphosphonate Drug Market Report Segments:
The global Bisphosphonate Drug market is segmented on the basis of:
Types
Alendronate, Risedronate, Zoledronic Acid, Other Bisphosphonate Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Postmenopausal Osteoporosis, Men with Osteoporosis, Paget’s Disease, Bone Loss Caused by Cancer Treatment, Osteoporosis Imperfecta in Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Teva
- Mylan
- Apotex Corp
- Cobalt Pharmaceuticals
- Genentech
- Novartis Pharmaceuticals
- Sanofi-Aventis
- Merck
Highlights of The Bisphosphonate Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alendronate
- Risedronate
- Zoledronic Acid
- Other Bisphosphonate Drug
- By Application:
- Postmenopausal Osteoporosis
- Men with Osteoporosis
- Paget’s Disease
- Bone Loss Caused by Cancer Treatment
- Osteoporosis Imperfecta in Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bisphosphonate Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bisphosphonates are a class of drugs used to treat bone diseases. They work by preventing the breakdown of bone tissue.
Some of the key players operating in the bisphosphonate drug market are Merck, Teva, Mylan, Apotex Corp, Cobalt Pharmaceuticals, Genentech, Novartis Pharmaceuticals, Sanofi-Aventis, Merck.
The bisphosphonate drug market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bisphosphonate Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bisphosphonate Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bisphosphonate Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bisphosphonate Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bisphosphonate Drug Market Size & Forecast, 2020-2028
4.5.1 Bisphosphonate Drug Market Size and Y-o-Y Growth
4.5.2 Bisphosphonate Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Alendronate
5.2.2 Risedronate
5.2.3 Zoledronic Acid
5.2.4 Other Bisphosphonate Drug
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Postmenopausal Osteoporosis
6.2.2 Men with Osteoporosis
6.2.3 Paget’s Disease
6.2.4 Bone Loss Caused by Cancer Treatment
6.2.5 Osteoporosis Imperfecta in Children
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bisphosphonate Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bisphosphonate Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Alendronate
9.6.2 Risedronate
9.6.3 Zoledronic Acid
9.6.4 Other Bisphosphonate Drug
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Postmenopausal Osteoporosis
9.10.2 Men with Osteoporosis
9.10.3 Paget’s Disease
9.10.4 Bone Loss Caused by Cancer Treatment
9.10.5 Osteoporosis Imperfecta in Children
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Alendronate
10.6.2 Risedronate
10.6.3 Zoledronic Acid
10.6.4 Other Bisphosphonate Drug
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Postmenopausal Osteoporosis
10.10.2 Men with Osteoporosis
10.10.3 Paget’s Disease
10.10.4 Bone Loss Caused by Cancer Treatment
10.10.5 Osteoporosis Imperfecta in Children
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Alendronate
11.6.2 Risedronate
11.6.3 Zoledronic Acid
11.6.4 Other Bisphosphonate Drug
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Postmenopausal Osteoporosis
11.10.2 Men with Osteoporosis
11.10.3 Paget’s Disease
11.10.4 Bone Loss Caused by Cancer Treatment
11.10.5 Osteoporosis Imperfecta in Children
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Alendronate
12.6.2 Risedronate
12.6.3 Zoledronic Acid
12.6.4 Other Bisphosphonate Drug
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Postmenopausal Osteoporosis
12.10.2 Men with Osteoporosis
12.10.3 Paget’s Disease
12.10.4 Bone Loss Caused by Cancer Treatment
12.10.5 Osteoporosis Imperfecta in Children
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Alendronate
13.6.2 Risedronate
13.6.3 Zoledronic Acid
13.6.4 Other Bisphosphonate Drug
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Postmenopausal Osteoporosis
13.10.2 Men with Osteoporosis
13.10.3 Paget’s Disease
13.10.4 Bone Loss Caused by Cancer Treatment
13.10.5 Osteoporosis Imperfecta in Children
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bisphosphonate Drug Market: Competitive Dashboard
14.2 Global Bisphosphonate Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Teva
14.3.3 Mylan
14.3.4 Apotex Corp
14.3.5 Cobalt Pharmaceuticals
14.3.6 Genentech
14.3.7 Novartis Pharmaceuticals
14.3.8 Sanofi-Aventis
14.3.9 Merck
